Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Antigen Discovery

Identification of MHC class II-restricted tumor antigens and intracellular delivery of antigenic peptides into dendritic cells

Rongfu Wang
Rongfu Wang
Baylor College of Medicine, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2003
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Increasing evidence from both human and animal studies indicates that CD4+ T cells play a central role in orchestrating the host immune response against cancer and other diseases (1). While a number of MHC class I-restricted tumor antigens have been identified, relatively little is known about MHC class II-restricted tumor antigens recognized by CD4+ T cells. Recently, we developed a genetic targeting expression (GTE) approach to identifying such MHC class II tumor antigens by screening an invariant chain (Ii)-cDNA fusion library (2). These studies have revealed several mutated or fusion proteins that serve as MHC class II-restricted tumor antigens (2, 3, 4). The second approach, also called "Reverse Immunology", is to identify CD4+ T-cell epitopes from a given candidate antigen. We have used this method to identify several T-cell epitopes from NY-ESO-1, a potentially important tumor antigen, by the combined use of DR4-transgenic mice and an in vitro stimulation with peptides predicted by a computer-assisted DR4-binding algorithm (5, 6). Meanwhile, in collaboration with Dr. Old and his colleagues we are currently working on identification of CD4+ T-cell epitopes derived from breast, colon and prostate cancer antigens that are originally identified by SEREX (7). I will summarize the current status of MHC class II-restricted tumor antigens as well as their potential biological relevance to tumor development and metastasis.

To develop effective cancer vaccines, tumor immunologists have used dendritic cells pulsed with antigenic peptides as promising cancer vaccines. However, human clinical trials conducted at multiple institutions have not yet realized this promise (8). We recently developed a novel strategy to enhance antitumor immunity by intracellular delivery of antigenic peptides into dendritic cells. Vaccination of mice with DCs intracellularly loaded with peptides showed a complete protective immunity against subsequent tumor challenge and potent therapeutic effects on tumor growth, while peptide-pulsed DCs failed to elicit antitumor immunity (9, 10). Enhanced antitumor immunity induced by intracellularly loaded peptide-DCs requires the participation of both CD4+ and CD8+ T-cell responses. Hence, the combined use of MHC class I and II restricted antigenic peptides and an effective delivery system may lead to developing potent cancer vaccines for the treatment of patients with cancer.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

 

  • Copyright © 2003 by Rongfu Wang

References

  1. 1.
    1. Wang RF
    . The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269–76.pmid:11323286
    OpenUrlCrossRefPubMed
  2. 2.
    1. Wang RF,
    2. Wang X,
    3. Atwood AC,
    4. Topalian SL,
    5. Rosenberg SA
    . Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351–4.pmid:10334988
    OpenUrlAbstract/FREE Full Text
  3. 3.
    1. Wang RF,
    2. Wang X,
    3. Rosenberg SA
    . Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med 1999;189:1659–68.pmid:10330445
    OpenUrlAbstract/FREE Full Text
  4. 4.
    1. Wang HY,
    2. Zhou J,
    3. Zhu K,
    4. Riker AI,
    5. Marincola FM,
    6. Wang RF
    . Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med 2002;195:1397–406.pmid:12045238
    OpenUrlAbstract/FREE Full Text
  5. 5.
    1. Zeng G,
    2. Touloukian CE,
    3. Wang X,
    4. Restifo NP,
    5. Rosenberg SA,
    6. Wang RF
    . Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000;165:1153–9.pmid:10878395
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Zeng G,
    2. Wang X,
    3. Robbins PF,
    4. Rosenberg SA,
    5. Wang RF
    . CD4+ T cell recognition of MHC class II-restricted epitopes from NY- ESO-1 presented by a prevalent HLA-DP4 allele: association with NY- ESO-1 antibody production. Proc Natl Acad Sci U S A 2001;98:3964–9.pmid:11259659
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Scanlan MJ,
    2. Welt S,
    3. Gordon CM,
    4. Chen YT,
    5. Gure AO,
    6. Stockert E,
    7. Jungbluth AA,
    8. Ritter G,
    9. Jager D,
    10. Jager E,
    11. Knuth A,
    12. Old LJ
    . Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002;62:4041–7.pmid:12124339
    OpenUrlAbstract/FREE Full Text
  8. 8.
    1. Dallal RM,
    2. Lotze MT
    . The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000;12:583–8.pmid:11007363
    OpenUrlCrossRefPubMed
  9. 9.
    1. Wang RF,
    2. Wang HY
    . Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 2002;20:149–54.pmid:11821860
    OpenUrlCrossRefPubMed
  10. 10.
    1. Wang HY,
    2. Fu T,
    3. Wang G,
    4. Zeng G,
    5. Perry-Lalley DM,
    6. Yang JC,
    7. Restifo NP,
    8. Hwu P,
    9. Wang RF
    . Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002;109:1463–70.pmid:12045260
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Immunity Archive: 3 (Suppl 1)
January 2003
Volume 3, Issue Suppl 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of MHC class II-restricted tumor antigens and intracellular delivery of antigenic peptides into dendritic cells
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
Citation Tools
Identification of MHC class II-restricted tumor antigens and intracellular delivery of antigenic peptides into dendritic cells
Rongfu Wang
Cancer Immun January 1 2003 (3) (Suppl 1) 9;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Identification of MHC class II-restricted tumor antigens and intracellular delivery of antigenic peptides into dendritic cells
Rongfu Wang
Cancer Immun January 1 2003 (3) (Suppl 1) 9;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Immunophenotyping of human tumor antigens
  • Identification and characterization of target molecules for antigen-specific cancer immunotherapy
Show more Cancer Antigen Discovery
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement